

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/141432 A3

(51) International Patent Classification:

A61K 31/33 (2006.01) A61K 31/438 (2006.01)
A61K 31/445 (2006.01) A61K 31/4523 (2006.01)

(21) International Application Number:

PCT/US2023/060787

(22) International Filing Date:

17 January 2023 (17.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/300,592	18 January 2022 (18.01.2022)	US
63/311,668	18 February 2022 (18.02.2022)	US
63/332,553	19 April 2022 (19.04.2022)	US
63/400,359	23 August 2022 (23.08.2022)	US
63/422,341	03 November 2022 (03.11.2022)	US

(71) Applicant: **MAZE THERAPEUTICS, INC.** [US/US];
171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: **LEE, Patrick Sang Tae**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **EWING, Todd Jonathan August**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **REID, Adam Neil**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SINZ, Christopher Joseph**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ZHANG, Birong**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **BRONNER, Sarah M.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **MORGANS, David John**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San


Francisco, California 94080 (US). **HOEK, Maarten**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ASSIMON, Victoria Anne**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ZIEBENHAUS, Chris**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SCHAMMEL, Alexander Wayne**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(74) Agent: **MCBRIAR, Mark D.** et al.; 200 Clarendon Street, 21st Floor, Boston, Massachusetts 02116 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: APOL1 INHIBITORS AND METHODS OF USE



Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

21 September 2023 (21.09.2023)